FHTX_OUT_1 [2025-04-04 11:21:05 -0400] 3173 Bytes | 832 tokens | Cum: 832 tkns (10.40% of 8k)
==========================================================================

Listen up, partner—it's 11:21:04 AM on Fri Apr 04, 2025 -0400, and I’m revved up about Foghorn Therapeutics (FHTX), climbing from 3.15 to 3.6. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Foghorn Therapeutics (FHTX)
IPO: 2020-10-23 (4 Years Ago)
Market Cap: $190,193,857
Shares Outstanding: 55,610,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Here’s the first list of news for Foghorn Therapeutics:

C1 - Apr-01-25 08:00AM - Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease
C2 - Mar-26-25 03:20AM - Foghorn: SMARCA4 Targeting Brings About Treating Up To 10% Of NSCLC Patients
C3 - Mar-25-25 04:35PM - Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting
C4 - Mar-25-25 04:35PM 08:00AM - Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica, an AI-Powered Drug Discovery Platform
C5 - Mar-20-25 05:19PM - Foghorn Therapeutics scales down ATM stock offering to $100M
C6 - Mar-06-25 06:05PM - Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates
C7 - Mar-06-25 06:05PM 04:05PM - Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook
C8 - Feb-27-25 10:00AM - Will Foghorn Therapeutics Inc. (FHTX) Report Negative Q4 Earnings? What You Should Know

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Foghorn Therapeutics (FHTX).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

FHTX_OUT_3 [2025-04-04 11:21:08 -0400] 696 Bytes | 218 tokens | Cum: 1053 tkns (13.16% of 8k)
==========================================================================

Showing C5 (chunk 1 of 1): C5:
**Foghorn Therapeutics scales down ATM stock offering to $100M**
Date: Mar-20-25 05:19PM
Source: (SeekingAlpha)
URL: https://seekingalpha.com/news/4423202-foghorn-therapeutics-scales-down-atm-stock-offering-100m?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

Error fetching article: 403 Client Error: Forbidden for url: https://seekingalpha.com/news/4423202-foghorn-therapeutics-scales-down-atm-stock-offering-100m?utm_source=finviz.com&utm_medium=referral&feed_item_type=news

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

FHTX_OUT_5 [2025-04-04 11:21:09 -0400] 997 Bytes | 292 tokens | Cum: 1392 tkns (17.40% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T12:00:00Z - Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potentia...
A2 - 2025-04-01T09:29:54Z - Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity T...
A3 - 2025-04-01T09:30:06Z - Why PVH Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - bioAffinity T...
A4 - 2025-03-26T15:14:13Z - FHTX stock touches 52-week low at $3.85 amid market challenges By Investing.com...
A5 - 2025-03-26T15:14:13Z - FHTX stock touches 52-week low at $3.85 amid market challenges By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

FHTX_OUT_7 [2025-04-04 11:21:12 -0400] 1098 Bytes | 296 tokens | Cum: 1690 tkns (21.12% of 8k)
==========================================================================

Showing A1 (chunk 1 of 6): A1:
**Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease - Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA)**Date: 2025-04-01Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/pressreleases/25/04/n44582882/flagship-pioneering-announces-agreement-between-pioneering-medicines-and-pfizer-to-discover-potentCollaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules

Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of innovative compounds that may become medicines targeting unmet needs

CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatfor

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

FHTX_OUT_9 [2025-04-04 11:21:13 -0400] 982 Bytes | 286 tokens | Cum: 2070 tkns (25.87% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-10-01T11:00:00Z - Foghorn Therapeutics to Participate in the BMO Oncology Summit
B2 - 2024-09-24T13:15:00Z - Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
B3 - 2024-09-03T20:48:52Z - Wall Street Analysts Think Foghorn Therapeutics Could Surge 81.16%: Read This Before Placing a Bet
B4 - 2024-09-03T11:00:00Z - Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer
B5 - 2024-08-08T11:00:00Z - Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
B6 - 2024-05-22T22:21:00Z - Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

FHTX_OUT_11 [2025-04-04 11:21:16 -0400] 757 Bytes | 215 tokens | Cum: 2287 tkns (28.59% of 8k)
==========================================================================

Showing B3 (chunk 1 of 1): B3:
**Wall Street Analysts Think Foghorn Therapeutics Could Surge 81.16%: Read This Before Placing a Bet**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/earnings/24/09/40676139/wall-street-analysts-think-foghorn-therapeutics-could-surge-81-16-read-this-before-placing-a-betWall Street analysts have set a mean price target of $15 for Foghorn Therapeutics (FHTX), indicating an 81.2% upside potential. The strong agreement among analysts on the company's earnings prospects suggests the stock could see an upside in the near term.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

FHTX_OUT_13 [2025-04-04 11:21:18 -0400] 1088 Bytes | 282 tokens | Cum: 2636 tkns (32.95% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-24 8-K Item 7.01 Regulation FD Disclosure.

Foghorn Therapeutics Inc. (the Company) is furnishing as Exhibit 99.1 to this Curr Report on Form 8-K a presentation dated March 2025, which the Company intends to use in meetings with or presentations to investors.

The information in th...

S2 - 2025-03-06 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our CONS financial statements and the related note...

S3 - 2025-03-06 8-K Item 2.02 Results of Oper and Fin Cond.

On March 6, 2025, Foghorn Therapeutics Inc. (the Company) issued a press release announcing certain of the Companys financial results for the year ended December 31, 2024. A copy of the press release is furnished as Exhib...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

FHTX_OUT_15 [2025-04-04 11:21:21 -0400] 1098 Bytes | 229 tokens | Cum: 2868 tkns (35.85% of 8k)
==========================================================================

Showing S2 (chunk 1 of 6): S2:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and the related notes to those statements included elsewhere in this Annual Report on Form 10-K. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed under Risk Factors and elsewhere in this Annual Report on Form 10-K.

Overview

Foghorn is a clinical stage, precision

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

FHTX_OUT_17 [2025-04-04 11:21:32 -0400] 5881 Bytes | 1649 tokens | Cum: 4607 tkns (57.59% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-------------------------+
| Volume: 145,226 | Perf Month: -20.44% | Option/Short: Yes / Yes | Sales Y/Y TTM: -33.83% |
+---------------------+-----------------------+-------------------------+-------------------------+
| Avg Volume: 134.75K | Perf Quarter: -22.00% | Short Float: 3.50% | ROE: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| Rel Volume: 3.83 | Index: RUT | Short Ratio: 7.24 | ROI: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| RSI (14): 40.07 | Market Cap: 199.09M | Short Interest: 0.98M | Sales Surprise: -60.26% |
+---------------------+-----------------------+-------------------------+-------------------------+
| ATR (14): 0.41 | Shs Outstand: 55.59M | Beta: 3.16 | EPS Surprise: 26.49% |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA20: -11.12% | Shs Float: 27.84M | Sales Q/Q: -50.49% | P/E: - |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA50: -20.35% | Inst Own: 41.62% | Sales past 5Y: 321.66% | Earnings: Mar 06 AMC |
+---------------------+-----------------------+-------------------------+-------------------------+
| SMA200: -43.18% | Insider Own: 49.95% | Employees: 112 | |
+---------------------+-----------------------+-------------------------+-------------------------+
| Perf Week: 1.70% | Insider Trans: 0.00% | Debt/Eq: - | |
+---------------------+-----------------------+-------------------------+-------------------------+

The next section covers any insider trading if any are accessible.

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by LaCascia Michael (Chief Legal Officer) on 2025-01-22
- Stock Option (right to buy): 126000 shares at $4.37 (D)

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by Bellon Steven F. (Chief Scientific Officer) on 2025-01-22
- Stock Option (right to buy): 140000 shares at $4.37 (D)

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by GOTTSCHALK ADRIAN (Chief Executive Officer) on 2025-01-22
- Stock Option (right to buy): 400000 shares at $4.37 (D)

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by Rivkin Anna (Chief Business Officer) on 2025-01-22
- Stock Option (right to buy): 50000 shares at $4.37 (D)

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by Costa Carlos (Chief People Officer) on 2025-01-22
- Stock Option (right to buy): 115000 shares at $4.37 (D)

Inside Trans: Foghorn Therapeutics Inc. (FHTX) by Humer Kristian (Chief Financial Officer) on 2025-01-22
- Stock Option (right to buy): 120000 shares at $4.37 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 22602000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -86620000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 3.72
Average Volume: 118005.87
30-Day High: 4.67
30-Day Low: 3.15

[Detailed Financials: TTM 2024]
- Total Assets: $283,982,000.0
- Total Liabilities: $329,510,000.0
- Total Equity: $-45,528,000.0
- Current Assets: $249,601,000.0
- Current Liabilities: $66,989,000.0

[Income Statement: TTM 2024]
- Revenue: $22,602,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.58

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-24,882,000.0

[Detailed Financials: FY 2024]
- Total Assets: $283,982,000.0
- Total Liabilities: $329,510,000.0
- Total Equity: $-45,528,000.0
- Current Assets: $249,601,000.0
- Current Liabilities: $66,989,000.0

[Income Statement: FY 2024]
- Revenue: $22,602,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -1.58

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-24,882,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

FHTX_OUT_19 [2025-04-04 11:21:34 -0400] 687 Bytes | 169 tokens | Cum: 5040 tkns (63.00% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

FHTX_IN_21 [2025-04-04 11:21:35 -0400] 126 Bytes | 29 tokens | Cum: 5099 tkns (63.74% of 8k)
==========================================================================

====================================
[2025-04-04 11:21:35] # Analysis Completed
Elapsed Time: 31.02 seconds